{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "5ebb5c45",
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "ca936341",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Name",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "DILI_labels",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Literature Search",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "claude__DILI Status",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "gpt5__DILI in clinic?",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "perplexity__DILI in Clinical Trials",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "grok__Clinical DILI Reported",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "futurehouse_labels",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "claude__Unnamed: 2",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "gpt5__One-line evidence",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "gpt5__Key source(s)",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "perplexity__Details",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "pubchem_smiles",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "dili_case_check Reasoning [Reasoning for the match decision]",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "dili_case_check Citations [Source citations for this match]",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "URL [Entity URL]",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "   ",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "standardized_smiles",
         "rawType": "object",
         "type": "string"
        }
       ],
       "ref": "a3d805aa-3c29-46f6-be2d-d38fe15c0a2a",
       "rows": [
        [
         "0",
         "Ocaliva",
         "1",
         "True",
         null,
         null,
         null,
         "1.0",
         "1.0",
         null,
         null,
         null,
         null,
         "CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCC(=O)O)C)C)O",
         null,
         null,
         null,
         null,
         "CC[C@H]1[C@@H](O)[C@@H]2[C@H](CC[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@H]23)[C@@]2(C)CC[C@@H](O)C[C@@H]12"
        ],
        [
         "1",
         "Evobrutinib",
         "1",
         "True",
         "1.0",
         "1.0",
         "1.0",
         "1.0",
         null,
         "2 MS patients developed liver injury in Phase III EVOLUTION trial; patients asymptomatic, liver enzymes normalized after discontinuation",
         "Trials saw ALT/AST ↑ and Hy’s-law–type cases; LFT monitoring.",
         "(The Lancet)",
         "FDA imposed partial clinical hold after liver toxicity cases in Phase III BTK-inhibitor trials.",
         "C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N",
         null,
         null,
         null,
         null,
         "C=CC(=O)N1CCC(CN=c2[nH]cnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1"
        ],
        [
         "2",
         "Orelabrutinib",
         "1",
         "True",
         "1.0",
         "1.0",
         "1.0",
         "1.0",
         null,
         "Drug-related cases of liver injury reported",
         "BTK inhibitor class has reported DILI; monitoring advised; specific orelabrutinib DILI is rare.",
         "(PMC)",
         "Partial clinical hold in December 2022 due to drug-related liver injury cases.",
         "C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C(C=C3)OC4=CC=CC=C4",
         null,
         null,
         null,
         null,
         "C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1"
        ],
        [
         "3",
         "Tolebrutinib",
         "1",
         "True",
         "1.0",
         "1.0",
         "1.0",
         "1.0",
         null,
         "Liver toxicity issues; one patient required liver transplant and died from complications",
         "MS program experienced serious liver injury cases/partial holds.",
         "(Alyftrek HCP)",
         "Partial Phase III hold following reversible DILI cases in trials.",
         "C=CC(=O)N1CCC[C@H](C1)N2C3=C(C(=NC=C3)N)N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5",
         null,
         null,
         null,
         null,
         "C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(=N)[nH]ccc32)C1"
        ],
        [
         "4",
         "Fenebrutinib",
         "1",
         "True",
         null,
         "1.0",
         "1.0",
         "1.0",
         null,
         null,
         "Trials reported liver enzyme elevations (class effect; monitor).",
         "(Gene)",
         "Hepatic transaminase grade ≥2 elevations more frequent (8.2% vs 2.8% placebo) in relapsing MS studies.",
         "C[C@H]1CN(CCN1C2=CN=C(C=C2)NC3=CC(=CN(C3=O)C)C4=C(C(=NC=C4)N5CCN6C7=C(CC(C7)(C)C)C=C6C5=O)CO)C8COC8",
         null,
         null,
         null,
         null,
         "C[C@H]1CN(C2COC2)CCN1c1ccc(=Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)[nH]c1"
        ],
        [
         "5",
         "Azelaprag",
         "1",
         "True",
         "1.0",
         "1.0",
         "1.0",
         null,
         null,
         "11 individuals in treatment groups experienced elevated liver enzyme levels in STRIDES Phase I trial",
         "Phase 2b/3 halted for transaminase elevations (liver safety signal).",
         "(FDA Access Data)",
         "STRIDES Phase I trial discontinued after 11 participants developed elevated liver enzyme levels.",
         "CC1=CC(=CN=C1)C2=NN=C(N2C3=C(C=CC=C3OC)OC)NS(=O)(=O)[C@@H](C)[C@H](C)C4=NC=C(C=N4)C",
         null,
         null,
         null,
         null,
         "COc1cccc(OC)c1-n1c(-c2cncc(C)c2)n[nH]c1=NS(=O)(=O)[C@@H](C)C(C)c1ncc(C)cn1"
        ],
        [
         "6",
         "TNG348",
         "1",
         "True",
         "1.0",
         "1.0",
         "1.0",
         null,
         null,
         "Grade 3 and life-threatening grade 4 liver function abnormalities after 8 weeks of treatment in Phase I/II study",
         "Trial discontinued due to liver toxicity/clinical hold.",
         "(PMC)",
         "Development halted for grade 3–4 liver function abnormalities in Phase I participants beyond 8 weeks.",
         "CN1C=C(N=C1C2=CC=C(C=C2)CN3C4=NC(=NC=C4N(C3=N)CC(F)(F)F)C5=C(N=CN=C5OC)C6CC6)C(F)(F)F",
         null,
         null,
         null,
         null,
         "COc1ncnc(C2CC2)c1-c1ncc2c(n1)n(Cc1ccc(-c3nc(C(F)(F)F)cn3C)cc1)c(=N)n2CC(F)(F)F"
        ],
        [
         "7",
         "Danuglipron",
         "1",
         "True",
         null,
         "1.0",
         "1.0",
         null,
         null,
         null,
         "Pfizer discontinued oral program citing potential DILI after LFT elevations.",
         "(U.S. Food and Drug Administration)",
         "Discontinued after one patient in Phase I experienced liver injury; enzymes recovered on discontinuation.",
         "C1CO[C@@H]1CN2C3=C(C=CC(=C3)C(=O)O)N=C2CN4CCC(CC4)C5=NC(=CC=C5)OCC6=C(C=C(C=C6)C#N)F",
         null,
         null,
         null,
         null,
         "N#Cc1ccc(COc2cccc(C3CCN(Cc4nc5ccc(C(=O)O)cc5n4C[C@@H]4CCO4)CC3)n2)c(F)c1"
        ],
        [
         "8",
         "Lotiglipron",
         "1",
         "True",
         null,
         "1.0",
         "1.0",
         null,
         null,
         null,
         "Pfizer terminated program for elevated transaminases/potential liver toxicity.",
         "(U.S. Food and Drug Administration)",
         "Development withdrawn in June 2023 after early trials showed elevated liver enzymes indicating hepatotoxicity.",
         "C[C@@]1(OC2=CC=CC(=C2O1)C3CCN(CC3)CC4=NC5=C(N4C[C@@H]6CCO6)C=C(C=C5)C(=O)O)C7=NC=C(C=C7)Cl",
         null,
         null,
         null,
         null,
         "C[C@]1(c2ccc(Cl)cn2)Oc2cccc(C3CCN(Cc4nc5ccc(C(=O)O)cc5n4C[C@@H]4CCO4)CC3)c2O1"
        ],
        [
         "9",
         "TAK-994",
         "1",
         "True",
         null,
         "1.0",
         "1.0",
         null,
         null,
         null,
         "Program stopped for hepatotoxicity; partial clinical hold reported.",
         "(RAPT Investors)",
         "Withdrawn from Phase II due to severe DILI; 3 patients met Hy’s Law criteria.",
         "CC(C)(C(=O)N1CC[C@@H]([C@@H]1CC2=C(C(=CC=C2)C3=CC(=CC(=C3)F)F)F)NS(=O)(=O)C)O.O",
         null,
         null,
         null,
         null,
         "CC(C)(O)C(=O)N1CC[C@H](NS(C)(=O)=O)[C@@H]1Cc1cccc(-c2cc(F)cc(F)c2)c1F"
        ],
        [
         "10",
         "Mitapivat",
         "1",
         "True",
         null,
         "1.0",
         null,
         null,
         null,
         null,
         "Label: LFT monitoring in long-term therapy; transaminase elevations noted.",
         "(FirstWord Pharma)",
         null,
         "C1CC1CN2CCN(CC2)C(=O)C3=CC=C(C=C3)NS(=O)(=O)C4=CC=CC5=C4N=CC=C5",
         null,
         null,
         null,
         null,
         "O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1"
        ],
        [
         "11",
         "Zelnecirnon",
         "1",
         "True",
         null,
         "1.0",
         null,
         null,
         null,
         null,
         "Program discontinued after severe liver injury case/clinical hold.",
         "(FDA Access Data)",
         null,
         "CC1=C(C(=NC(=N1)N2CC(C2)[C@H]3CCCN(C3)C4CC(C4)(C)C(=O)O)N[C@H](C)C5=C(C=C(C=C5)Cl)Cl)Cl",
         null,
         null,
         null,
         null,
         "Cc1[nH]c(N2CC([C@H]3CCCN(C4CC(C)(C(=O)O)C4)C3)C2)nc(=N[C@H](C)c2ccc(Cl)cc2Cl)c1Cl"
        ],
        [
         "12",
         "Icovamenib",
         "1",
         "True",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "C=CC(=O)N[C@@H]1CCCN(C1)CC2=CC(=NC=C2)C(=O)NC3=CC=C(C=C3)C4=CC5=C(N4)N=CN=C5N6CCOCC6",
         null,
         null,
         null,
         null,
         "C=CC(=O)N[C@@H]1CCCN(Cc2ccnc(C(=O)Nc3ccc(-c4cc5c(N6CCOCC6)ncnc5[nH]4)cc3)c2)C1"
        ],
        [
         "13",
         "Elafibranor",
         "1",
         null,
         null,
         "1.0",
         "1.0",
         "1.0",
         "1.0",
         null,
         "PBC label includes liver test monitoring/impairment guidance (no boxed DILI).",
         "(Ohtuvayre HCP)",
         "DILI in three patients (one at 80 mg, two at 1.5× dose); one presented as autoimmune-like hepatitis.",
         "CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)/C=C/C(=O)C2=CC=C(C=C2)SC",
         null,
         null,
         null,
         null,
         "CSc1ccc(C(=O)/C=C/c2cc(C)c(OC(C)(C)C(=O)O)c(C)c2)cc1"
        ],
        [
         "14",
         "Momelotinib",
         "1",
         null,
         null,
         "1.0",
         "1.0",
         "1.0",
         "1.0",
         null,
         "Label: “OJJAARA can cause hepatotoxicity;” baseline & monthly LFTs first 6 mo.",
         "(FDA Access Data, ojjaarahcp.com)",
         "Grade 3–4 ALT elevations in 4%; AST/ALP in 2% each; grade 1–2 increases also reported.",
         "C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N",
         null,
         null,
         null,
         null,
         "N#CCNC(=O)c1ccc(-c2cc[nH]c(=Nc3ccc(N4CCOCC4)cc3)n2)cc1"
        ],
        [
         "15",
         "Resmetirom",
         "1",
         null,
         null,
         "1.0",
         "1.0",
         "1.0",
         "1.0",
         null,
         "Label/HCP: explicit Hepatotoxicity warning; monitor; 1 notable case in trials.",
         "(FDA Access Data, Rezdiffra® (resmetirom) HCP Website)",
         "Three of four reviewed cases probable DILI; one Hy’s Law case with autoimmune-like hepatitis phenotype.",
         "CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl",
         null,
         null,
         null,
         null,
         "CC(C)c1cc(Oc2c(Cl)cc(-n3nc(C#N)c(=O)[nH]c3=O)cc2Cl)n[nH]c1=O"
        ],
        [
         "16",
         "Vadadustat",
         "1",
         null,
         null,
         "1.0",
         "1.0",
         "1.0",
         "1.0",
         null,
         "Label: monitor ALT/AST & bilirubin; not recommended in cirrhosis/acute liver disease.",
         "(FDA Access Data)",
         "Several probable DILI cases, including one Hy’s Law–type event in premarketing application.",
         "C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O",
         null,
         null,
         null,
         null,
         "O=C(O)CNC(=O)c1ncc(-c2cccc(Cl)c2)cc1O"
        ],
        [
         "17",
         "Tovorafenib",
         "1",
         null,
         null,
         "1.0",
         "1.0",
         null,
         "1.0",
         null,
         "Label: transaminase elevations; LFT monitoring guidance.",
         "(U.S. Food and Drug Administration)",
         "Serum enzyme elevations and liver injury likely due to direct BRAF/MAPK pathway–mediated toxicity.",
         "C[C@H](C1=NC=C(S1)C(=O)NC2=NC=C(C(=C2)C(F)(F)F)Cl)NC(=O)C3=C(C(=NC=N3)N)Cl",
         null,
         null,
         null,
         null,
         "CC(NC(=O)c1[nH]cnc(=N)c1Cl)c1ncc(C(=O)N=c2cc(C(F)(F)F)c(Cl)c[nH]2)s1"
        ],
        [
         "18",
         "Seladelpar",
         "0",
         null,
         null,
         "1.0",
         null,
         null,
         "1.0",
         null,
         "HCP/label: dose-related transaminase increases at high doses; monitor (10 mg label dose).",
         "(livdelzihcp.com, Gilead)",
         null,
         "CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC(=C(C=C2)OCC(=O)O)C",
         null,
         null,
         null,
         null,
         "CCO[C@H](COc1ccc(C(F)(F)F)cc1)CSc1ccc(OCC(=O)O)c(C)c1"
        ],
        [
         "19",
         "Elacestrant",
         "0",
         null,
         null,
         null,
         null,
         null,
         "1.0",
         null,
         null,
         null,
         null,
         "CCNCCC1=CC=C(C=C1)CN(CC)C2=C(C=CC(=C2)OC)[C@@H]3CCC4=C(C3)C=CC(=C4)O",
         null,
         null,
         null,
         null,
         "CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1"
        ],
        [
         "20",
         "Danicopan",
         "0",
         null,
         null,
         "1.0",
         "1.0",
         null,
         null,
         null,
         "Label/EMA: transaminase/bilirubin increases monitored; LFT monitoring described in review.",
         "(European Medicines Agency (EMA), FDA Access Data)",
         "Two subjects with probable DILI; ten additional suspected cases deemed unlikely.",
         "CC1=NC=C(C=N1)C2=CC3=C(C=C2)N(N=C3C(=O)C)CC(=O)N4C[C@@H](C[C@H]4C(=O)NC5=NC(=CC=C5)Br)F",
         null,
         null,
         null,
         null,
         "CC(=O)c1nn(CC(=O)N2C[C@H](F)CC2C(=O)N=c2cccc(Br)[nH]2)c2ccc(-c3cnc(C)nc3)cc12"
        ],
        [
         "21",
         "Ensartinib",
         "0",
         null,
         null,
         "1.0",
         "1.0",
         null,
         null,
         null,
         "Label & LiverTox recommend baseline/frequent LFT monitoring (ALK TKI).",
         "(FDA Access Data, NCBI)",
         "ALK-inhibitor–associated hepatotoxicity; severe hyperbilirubinemia requiring artificial liver support reported.",
         "C[C@@H]1CN(C[C@@H](N1)C)C(=O)C2=CC=C(C=C2)NC(=O)C3=NN=C(C(=C3)O[C@H](C)C4=C(C=CC(=C4Cl)F)Cl)N",
         null,
         null,
         null,
         null,
         "C[C@@H]1CN(C(=O)c2ccc(NC(=O)c3cc(O[C@H](C)c4c(Cl)ccc(F)c4Cl)c(=N)[nH]n3)cc2)C[C@H](C)N1"
        ],
        [
         "22",
         "Pirtobrutinib",
         "0",
         null,
         null,
         "1.0",
         "1.0",
         null,
         null,
         null,
         "Label warns “hepatotoxicity (including DILI)” and to monitor LFTs.",
         null,
         "Severe hepatotoxicity with Hy’s Law cases; FDA label includes hepatotoxicity warning.",
         "C[C@@H](C(F)(F)F)N1C(=C(C(=N1)C2=CC=C(C=C2)CNC(=O)C3=C(C=CC(=C3)F)OC)C(=O)N)N",
         null,
         null,
         null,
         null,
         "COc1ccc(F)cc1C(=O)NCc1ccc(-c2[nH]n([C@@H](C)C(F)(F)F)c(=N)c2C(N)=O)cc1"
        ],
        [
         "23",
         "Quizartinib",
         "0",
         null,
         null,
         "1.0",
         "1.0",
         null,
         null,
         null,
         "LFT elevations reported; LiverTox: rare acute injury/“hepatic failure” events attributed to other causes.",
         "(NCBI)",
         "High rate of liver enzyme elevations during therapy, comparable to control arms.",
         "CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3",
         null,
         null,
         null,
         null,
         "CC(C)(C)c1cc(=NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)[nH]o1"
        ],
        [
         "24",
         "Ritlecitinib",
         "0",
         null,
         null,
         "1.0",
         "1.0",
         null,
         null,
         null,
         "Label: ALT/AST ≥5×ULN occurred; investigate/interrupt if DILI suspected.",
         "(FDA Access Data, litfulo.pfizerpro.com)",
         "1–3% incidence of aminotransferase elevations; label warns of DILI risk.",
         "C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3",
         null,
         null,
         null,
         null,
         "C=CC(=O)N1C[C@H](N=c2[nH]cnc3[nH]ccc23)CC[C@@H]1C"
        ],
        [
         "25",
         "Ceftobiprole medocaril",
         "0",
         null,
         null,
         "1.0",
         null,
         null,
         null,
         null,
         "Label: “hepatic enzyme increased / bilirubin increased” among common AEs.",
         "(FDA Access Data)",
         null,
         "CC1=C(OC(=O)O1)COC(=O)N2CC[C@H](C2)N3CC/C(=C\\C4=C(N5[C@@H]([C@@H](C5=O)NC(=O)/C(=N\\O)/C6=NSC(=N6)N)SC4)C(=O)O)/C3=O",
         null,
         null,
         null,
         null,
         "Cc1oc(=O)oc1COC(=O)N1CC[C@@H](n2ccc(C=C3CS[C@@H]4C(NC(=O)C(=NO)c5nc(=N)s[nH]5)C(=O)N4C3C(=O)O)c2O)C1"
        ],
        [
         "26",
         "Inavolisib",
         "0",
         null,
         null,
         "1.0",
         null,
         null,
         null,
         null,
         "Label/refs: transaminase elevations; routine monitoring in oncology regimens.",
         "(FDA Access Data, NCBI)",
         null,
         "C[C@@H](C(=O)N)NC1=CC2=C(C=C1)C3=NC(=CN3CCO2)N4[C@@H](COC4=O)C(F)F",
         null,
         null,
         null,
         null,
         "CC(Nc1ccc2c(c1)OCCn1cc(N3C(=O)OC[C@H]3C(F)F)nc1-2)C(N)=O"
        ],
        [
         "27",
         "Palovarotene",
         "0",
         null,
         null,
         "1.0",
         null,
         null,
         null,
         null,
         "Label notes transaminase elevations/“hepatic cytolysis;” monitor.",
         "(jaypirca.lilly.com)",
         null,
         "CC1(CCC(C2=C1C=C(C(=C2)/C=C/C3=CC=C(C=C3)C(=O)O)CN4C=CC=N4)(C)C)C",
         null,
         null,
         null,
         null,
         "CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21"
        ],
        [
         "28",
         "Revumenib",
         "0",
         null,
         null,
         "1.0",
         null,
         null,
         null,
         null,
         "Label/refs: LFT elevations monitored in trials (menin inhibitor class).",
         "(FDA Access Data)",
         null,
         "CCN(C(C)C)C(=O)C1=C(C=CC(=C1)F)OC2=CN=CN=C2N3CC4(C3)CCN(CC4)CC5CCC(CC5)NS(=O)(=O)CC",
         null,
         null,
         null,
         null,
         "CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(CC3CCC(NS(=O)(=O)CC)CC3)CC2)C1)C(C)C"
        ],
        [
         "29",
         "Acoramidis",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC1=C(C(=NN1)C)CCCOC2=C(C=CC(=C2)C(=O)O)F",
         null,
         null,
         null,
         null,
         "Cc1n[nH]c(C)c1CCCOc1cc(C(=O)O)ccc1F"
        ],
        [
         "30",
         "Arimoclomol",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "C1CCN(CC1)C[C@H](CON=C(C2=C[N+](=CC=C2)[O-])Cl)O",
         null,
         null,
         null,
         null,
         "[O-][n+]1cccc(C(Cl)=NOC[C@H](O)CN2CCCCC2)c1"
        ],
        [
         "31",
         "Bexagliflozin",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl",
         null,
         null,
         null,
         null,
         "OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O"
        ],
        [
         "32",
         "Crinecerfont",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC1=C(C=C(C=C1)[C@H](CC2CC2)N(CC#C)C3=NC(=C(S3)C)C4=C(C=C(C(=C4)C)OC)Cl)F",
         null,
         null,
         null,
         null,
         "C#CCN(c1nc(-c2cc(C)c(OC)cc2Cl)c(C)s1)[C@@H](CC1CC1)c1ccc(C)c(F)c1"
        ],
        [
         "33",
         "Ensifentrine",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC1=CC(=C(C(=C1)C)N=C2C=C3C4=CC(=C(C=C4CCN3C(=O)N2CCNC(=O)N)OC)OC)C",
         null,
         null,
         null,
         null,
         "COc1cc2c(cc1OC)-c1cc(=Nc3c(C)cc(C)cc3C)n(CCNC(N)=O)c(=O)n1CC2"
        ],
        [
         "34",
         "Gepirone",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3=NC=CC=N3)C",
         null,
         null,
         null,
         null,
         "CC1(C)CC(=O)N(CCCCN2CCN(c3ncccn3)CC2)C(=O)C1"
        ],
        [
         "35",
         "Givinostat",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO",
         null,
         null,
         null,
         null,
         "CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(C(O)=NO)cc3)ccc2c1"
        ],
        [
         "36",
         "Iptacopan",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CCO[C@H]1CCN([C@@H](C1)C2=CC=C(C=C2)C(=O)O)CC3=C(C=C(C4=C3C=CN4)C)OC",
         null,
         null,
         null,
         null,
         "CCO[C@H]1CCN(Cc2c(OC)cc(C)c3[nH]ccc23)C(c2ccc(C(=O)O)cc2)C1"
        ],
        [
         "37",
         "Landiolol",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC1(OC[C@H](O1)COC(=O)CCC2=CC=C(C=C2)OC[C@H](CNCCNC(=O)N3CCOCC3)O)C",
         null,
         null,
         null,
         null,
         "CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1"
        ],
        [
         "38",
         "Levacetylleucine",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC(C)C[C@@H](C(=O)O)NC(=O)C",
         null,
         null,
         null,
         null,
         "CC(=O)NC(CC(C)C)C(=O)O"
        ],
        [
         "39",
         "Lotilaner",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC1=C(SC(=C1)C2=NO[C@@](C2)(C3=CC(=C(C(=C3)Cl)Cl)Cl)C(F)(F)F)C(=O)NCC(=O)NCC(F)(F)F",
         null,
         null,
         null,
         null,
         "Cc1cc(C2=NO[C@@](c3cc(Cl)c(Cl)c(Cl)c3)(C(F)(F)F)C2)sc1C(=O)NCC(=O)NCC(F)(F)F"
        ],
        [
         "40",
         "Sulopenem etzadroxil",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CCC(CC)C(=O)OCOC(=O)C1=C(S[C@H]2N1C(=O)[C@@H]2[C@@H](C)O)S[C@H]3CC[S@@](=O)C3",
         null,
         null,
         null,
         null,
         "CCC(CC)C(=O)OCOC(=O)C1=C(S[C@H]2CC[S@@+]([O-])C2)S[C@@H]2C([C@@H](C)O)C(=O)N12"
        ],
        [
         "41",
         "Tezacaftor",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC(C)(CO)C1=CC2=CC(=C(C=C2N1C[C@H](CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F",
         null,
         null,
         null,
         null,
         "CC(C)(CO)c1cc2cc(NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c(F)cc2n1C[C@@H](O)CO"
        ],
        [
         "42",
         "Vanzacaftor",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC1(C[C@@H]2CCCNC3=NC(=CC=C3)S(=O)(=O)NC(=O)C4=C(N1C2)N=C(C=C4)N5C=CC(=N5)OCCC6C7(C68CC8)CC7)C",
         null,
         null,
         null,
         null,
         "CC1(C)C[C@@H]2CCCNc3cccc(n3)S(=O)(=O)NC(=O)c3ccc(-n4ccc(OCCC5C6(CC6)C56CC6)n4)nc3N1C2"
        ],
        [
         "43",
         "Cefcapene pivoxil",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC/C=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)OCOC(=O)C(C)(C)C",
         "No clear, documented case of drug-induced liver injury specifically attributed to cefcapene pivoxil was found in the provided sources.",
         null,
         "amjcaserep.com/abstract/full/idArt/928587",
         null,
         "CCCC(C(=O)N=C1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(COC(N)=O)CSC12)c1csc(=N)[nH]1"
        ],
        [
         "44",
         "Ornithine phenylacetate",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "C1=CC=C(C=C1)CC(=O)O.C(C[C@@H](C(=O)O)N)CN",
         "Clinical safety/PK study (PMC5826861) and the randomized phase 2b trial report no safety signals or evidence that OP causes drug-induced liver injury; adverse event rates were similar to placebo.",
         null,
         "cghjournal.org/article/s1542-3565(20)31432-4/fulltext",
         null,
         "NCCCC(N)C(=O)O"
        ],
        [
         "45",
         "S-Adenosylmethionine",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "C[S+](CC[C@@H](C(=O)[O-])N)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O",
         "Available peer-reviewed reviews and curated drug/chemical databases describe SAMe as a hepatoprotective/endogenous agent used therapeutically in liver disease and for prevention/management of chemotherapy-associated liver injury; they do not identify SAMe as a causative agent of DILI.",
         null,
         "pubchem.ncbi.nlm.nih.gov/compound/S-adenosylmethionine",
         null,
         "C[S+](CCC(N)C(=O)[O-])C[C@H]1O[C@@H](n2cnc3c(=N)[nH]cnc32)[C@H](O)[C@@H]1O"
        ],
        [
         "46",
         "Pipemidic acid",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CCN1C=C(C(=O)C2=CN=C(N=C21)N3CCNCC3)C(=O)O",
         "No clear primary clinical case report or regulatory/registry entry identifying pipemidic acid as a confirmed cause of drug-induced liver injury was found in the provided sources. Some secondary sources note possible effects on liver function and NCATS lists contraindication in severe hepatic insufficiency, but that is not the same as documented drug-induced liver injury cases.",
         null,
         "drugs.ncats.io/drug/LT12J5HVR8",
         null,
         "CCn1cc(C(=O)O)c(=O)c2cnc(N3CCNCC3)nc21"
        ],
        [
         "47",
         "Ceftobiprole",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "C1CNC[C@@H]1N2CC/C(=C\\C3=C(N4[C@@H]([C@@H](C4=O)NC(=O)/C(=N\\O)/C5=NSC(=N5)N)SC3)C(=O)O)/C2=O",
         "Ceftobiprole is not established as a DILI-positive compound in clinical trials or regulatory review. Trial and FDA data found no Hy's law cases attributable to the drug and concluded an association with clinically significant DILI is unlikely; real-world studies report increased liver-related AEs in patients with preexisting hepatic impairment or immunocompromise but found no new DILI safety signal.",
         "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218275Orig1s000IntegratedR.pdf, https://pmc.ncbi.nlm.nih.gov/articles/PMC6755345/",
         "accessdata.fda.gov/drugsatfda_docs/nda/2024/218275Orig1s000IntegratedR.pdf",
         null,
         "N=c1[nH]c(C(=NO)C(=O)NC2C(=O)N3C(C(=O)O)=C(Cc4ccn([C@@H]5CCNC5)c4O)CS[C@H]23)ns1"
        ],
        [
         "48",
         "Norepinephrine",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "C1=CC(=C(C=C1[C@H](CN)O)O)O",
         "The FDA DILIst dataset does not classify Norepinephrine as a DILI-positive agent. While experimental studies show potential hepatotoxicity under specific conditions, clinical DILI attribution is not established.",
         "https://pubchem.ncbi.nlm.nih.gov/compound/Norepinephrine-hydrochloride",
         "fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset",
         null,
         "NC[C@H](O)c1ccc(O)c(O)c1"
        ],
        [
         "49",
         "Tebipenem",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1SC3CN(C3)C4=NCCS4)C(=O)O)[C@@H](C)O",
         "Clinical trials reported only rare, mild ALT/AST elevations (<=1%) and explicitly stated that no patients met Hy's law criteria for drug-induced liver injury. No clinical DILI cases meeting Hy's law or severe DILI have been reported in available human studies.",
         "https://www.nejm.org/doi/full/10.1056/NEJMoa2105462",
         "nejm.org/doi/full/10.1056/NEJMoa2105462",
         null,
         "CC1=C(SC2CN(C3=NCCS3)C2)C(C(=O)O)N2C(=O)C([C@@H](C)O)[C@@H]12"
        ]
       ],
       "shape": {
        "columns": 18,
        "rows": 357
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Name</th>\n",
       "      <th>DILI_labels</th>\n",
       "      <th>Literature Search</th>\n",
       "      <th>claude__DILI Status</th>\n",
       "      <th>gpt5__DILI in clinic?</th>\n",
       "      <th>perplexity__DILI in Clinical Trials</th>\n",
       "      <th>grok__Clinical DILI Reported</th>\n",
       "      <th>futurehouse_labels</th>\n",
       "      <th>claude__Unnamed: 2</th>\n",
       "      <th>gpt5__One-line evidence</th>\n",
       "      <th>gpt5__Key source(s)</th>\n",
       "      <th>perplexity__Details</th>\n",
       "      <th>pubchem_smiles</th>\n",
       "      <th>dili_case_check Reasoning [Reasoning for the match decision]</th>\n",
       "      <th>dili_case_check Citations [Source citations for this match]</th>\n",
       "      <th>URL [Entity URL]</th>\n",
       "      <th></th>\n",
       "      <th>standardized_smiles</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Ocaliva</td>\n",
       "      <td>1</td>\n",
       "      <td>True</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CC[C@H]1[C@@H](O)[C@@H]2[C@H](CC[C@]3(C)[C@@H]...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Evobrutinib</td>\n",
       "      <td>1</td>\n",
       "      <td>True</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2 MS patients developed liver injury in Phase ...</td>\n",
       "      <td>Trials saw ALT/AST ↑ and Hy’s-law–type cases; ...</td>\n",
       "      <td>(The Lancet)</td>\n",
       "      <td>FDA imposed partial clinical hold after liver ...</td>\n",
       "      <td>C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)O...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>C=CC(=O)N1CCC(CN=c2[nH]cnc(N)c2-c2ccc(Oc3ccccc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Orelabrutinib</td>\n",
       "      <td>1</td>\n",
       "      <td>True</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Drug-related cases of liver injury reported</td>\n",
       "      <td>BTK inhibitor class has reported DILI; monitor...</td>\n",
       "      <td>(PMC)</td>\n",
       "      <td>Partial clinical hold in December 2022 due to ...</td>\n",
       "      <td>C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Tolebrutinib</td>\n",
       "      <td>1</td>\n",
       "      <td>True</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Liver toxicity issues; one patient required li...</td>\n",
       "      <td>MS program experienced serious liver injury ca...</td>\n",
       "      <td>(Alyftrek HCP)</td>\n",
       "      <td>Partial Phase III hold following reversible DI...</td>\n",
       "      <td>C=CC(=O)N1CCC[C@H](C1)N2C3=C(C(=NC=C3)N)N(C2=O...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Fenebrutinib</td>\n",
       "      <td>1</td>\n",
       "      <td>True</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Trials reported liver enzyme elevations (class...</td>\n",
       "      <td>(Gene)</td>\n",
       "      <td>Hepatic transaminase grade ≥2 elevations more ...</td>\n",
       "      <td>C[C@H]1CN(CCN1C2=CN=C(C=C2)NC3=CC(=CN(C3=O)C)C...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>C[C@H]1CN(C2COC2)CCN1c1ccc(=Nc2cc(-c3ccnc(N4CC...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>352</th>\n",
       "      <td>Pergolide</td>\n",
       "      <td>1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC</td>\n",
       "      <td>Multiple authoritative sources, including Live...</td>\n",
       "      <td>https://pubchem.ncbi.nlm.nih.gov/compound/Perg...</td>\n",
       "      <td>ncbi.nlm.nih.gov/books/NBK548593</td>\n",
       "      <td>https://www.ncbi.nlm.nih.gov/books/NBK548593/,...</td>\n",
       "      <td>CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>353</th>\n",
       "      <td>Anidulafungin</td>\n",
       "      <td>1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C...</td>\n",
       "      <td>Anidulafungin has documented reports/signals o...</td>\n",
       "      <td>https://www.sciencedirect.com/topics/biochemis...</td>\n",
       "      <td>frontiersin.org/journals/pharmacology/articles...</td>\n",
       "      <td>https://www.ncbi.nlm.nih.gov/books/NBK548299/,...</td>\n",
       "      <td>CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)NC4C[C@@H](O)[C...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>354</th>\n",
       "      <td>Ibrutinib</td>\n",
       "      <td>1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>C=CC(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=C...</td>\n",
       "      <td>Multiple sources, including LiverTox and case ...</td>\n",
       "      <td>https://journals.lww.com/ajg/fulltext/2017/100...</td>\n",
       "      <td>ncbi.nlm.nih.gov/books/NBK548449</td>\n",
       "      <td>https://onlinelibrary.wiley.com/doi/full/10.10...</td>\n",
       "      <td>C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>355</th>\n",
       "      <td>Pazufloxacin</td>\n",
       "      <td>1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C...</td>\n",
       "      <td>Pazufloxacin is listed in the FDA Drug-Induced...</td>\n",
       "      <td>https://pmc.ncbi.nlm.nih.gov/articles/PMC61815...</td>\n",
       "      <td>fda.gov/science-research/liver-toxicity-knowle...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>C[C@H]1COc2c(C3(N)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>356</th>\n",
       "      <td>Cefiderocol</td>\n",
       "      <td>1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2...</td>\n",
       "      <td>Cefiderocol has reported transient aminotransf...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ncbi.nlm.nih.gov/books/NBK547862</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CC(C)(ON=C(C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>357 rows × 18 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "              Name  DILI_labels Literature Search  claude__DILI Status  \\\n",
       "0          Ocaliva            1              True                  NaN   \n",
       "1      Evobrutinib            1              True                  1.0   \n",
       "2    Orelabrutinib            1              True                  1.0   \n",
       "3     Tolebrutinib            1              True                  1.0   \n",
       "4     Fenebrutinib            1              True                  NaN   \n",
       "..             ...          ...               ...                  ...   \n",
       "352      Pergolide            1               NaN                  NaN   \n",
       "353  Anidulafungin            1               NaN                  NaN   \n",
       "354      Ibrutinib            1               NaN                  NaN   \n",
       "355   Pazufloxacin            1               NaN                  NaN   \n",
       "356    Cefiderocol            1               NaN                  NaN   \n",
       "\n",
       "     gpt5__DILI in clinic?  perplexity__DILI in Clinical Trials  \\\n",
       "0                      NaN                                  NaN   \n",
       "1                      1.0                                  1.0   \n",
       "2                      1.0                                  1.0   \n",
       "3                      1.0                                  1.0   \n",
       "4                      1.0                                  1.0   \n",
       "..                     ...                                  ...   \n",
       "352                    NaN                                  NaN   \n",
       "353                    NaN                                  NaN   \n",
       "354                    NaN                                  NaN   \n",
       "355                    NaN                                  NaN   \n",
       "356                    NaN                                  NaN   \n",
       "\n",
       "     grok__Clinical DILI Reported  futurehouse_labels  \\\n",
       "0                             1.0                 1.0   \n",
       "1                             1.0                 NaN   \n",
       "2                             1.0                 NaN   \n",
       "3                             1.0                 NaN   \n",
       "4                             1.0                 NaN   \n",
       "..                            ...                 ...   \n",
       "352                           NaN                 NaN   \n",
       "353                           NaN                 NaN   \n",
       "354                           NaN                 NaN   \n",
       "355                           NaN                 NaN   \n",
       "356                           NaN                 NaN   \n",
       "\n",
       "                                    claude__Unnamed: 2  \\\n",
       "0                                                  NaN   \n",
       "1    2 MS patients developed liver injury in Phase ...   \n",
       "2          Drug-related cases of liver injury reported   \n",
       "3    Liver toxicity issues; one patient required li...   \n",
       "4                                                  NaN   \n",
       "..                                                 ...   \n",
       "352                                                NaN   \n",
       "353                                                NaN   \n",
       "354                                                NaN   \n",
       "355                                                NaN   \n",
       "356                                                NaN   \n",
       "\n",
       "                               gpt5__One-line evidence gpt5__Key source(s)  \\\n",
       "0                                                  NaN                 NaN   \n",
       "1    Trials saw ALT/AST ↑ and Hy’s-law–type cases; ...        (The Lancet)   \n",
       "2    BTK inhibitor class has reported DILI; monitor...               (PMC)   \n",
       "3    MS program experienced serious liver injury ca...      (Alyftrek HCP)   \n",
       "4    Trials reported liver enzyme elevations (class...              (Gene)   \n",
       "..                                                 ...                 ...   \n",
       "352                                                NaN                 NaN   \n",
       "353                                                NaN                 NaN   \n",
       "354                                                NaN                 NaN   \n",
       "355                                                NaN                 NaN   \n",
       "356                                                NaN                 NaN   \n",
       "\n",
       "                                   perplexity__Details  \\\n",
       "0                                                  NaN   \n",
       "1    FDA imposed partial clinical hold after liver ...   \n",
       "2    Partial clinical hold in December 2022 due to ...   \n",
       "3    Partial Phase III hold following reversible DI...   \n",
       "4    Hepatic transaminase grade ≥2 elevations more ...   \n",
       "..                                                 ...   \n",
       "352                                                NaN   \n",
       "353                                                NaN   \n",
       "354                                                NaN   \n",
       "355                                                NaN   \n",
       "356                                                NaN   \n",
       "\n",
       "                                        pubchem_smiles  \\\n",
       "0    CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4...   \n",
       "1    C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)O...   \n",
       "2    C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C...   \n",
       "3    C=CC(=O)N1CCC[C@H](C1)N2C3=C(C(=NC=C3)N)N(C2=O...   \n",
       "4    C[C@H]1CN(CCN1C2=CN=C(C=C2)NC3=CC(=CN(C3=O)C)C...   \n",
       "..                                                 ...   \n",
       "352  CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC   \n",
       "353  CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C...   \n",
       "354  C=CC(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=C...   \n",
       "355  C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C...   \n",
       "356  CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2...   \n",
       "\n",
       "    dili_case_check Reasoning [Reasoning for the match decision]  \\\n",
       "0                                                  NaN             \n",
       "1                                                  NaN             \n",
       "2                                                  NaN             \n",
       "3                                                  NaN             \n",
       "4                                                  NaN             \n",
       "..                                                 ...             \n",
       "352  Multiple authoritative sources, including Live...             \n",
       "353  Anidulafungin has documented reports/signals o...             \n",
       "354  Multiple sources, including LiverTox and case ...             \n",
       "355  Pazufloxacin is listed in the FDA Drug-Induced...             \n",
       "356  Cefiderocol has reported transient aminotransf...             \n",
       "\n",
       "    dili_case_check Citations [Source citations for this match]  \\\n",
       "0                                                  NaN            \n",
       "1                                                  NaN            \n",
       "2                                                  NaN            \n",
       "3                                                  NaN            \n",
       "4                                                  NaN            \n",
       "..                                                 ...            \n",
       "352  https://pubchem.ncbi.nlm.nih.gov/compound/Perg...            \n",
       "353  https://www.sciencedirect.com/topics/biochemis...            \n",
       "354  https://journals.lww.com/ajg/fulltext/2017/100...            \n",
       "355  https://pmc.ncbi.nlm.nih.gov/articles/PMC61815...            \n",
       "356                                                NaN            \n",
       "\n",
       "                                      URL [Entity URL]  \\\n",
       "0                                                  NaN   \n",
       "1                                                  NaN   \n",
       "2                                                  NaN   \n",
       "3                                                  NaN   \n",
       "4                                                  NaN   \n",
       "..                                                 ...   \n",
       "352                   ncbi.nlm.nih.gov/books/NBK548593   \n",
       "353  frontiersin.org/journals/pharmacology/articles...   \n",
       "354                   ncbi.nlm.nih.gov/books/NBK548449   \n",
       "355  fda.gov/science-research/liver-toxicity-knowle...   \n",
       "356                   ncbi.nlm.nih.gov/books/NBK547862   \n",
       "\n",
       "                                                        \\\n",
       "0                                                  NaN   \n",
       "1                                                  NaN   \n",
       "2                                                  NaN   \n",
       "3                                                  NaN   \n",
       "4                                                  NaN   \n",
       "..                                                 ...   \n",
       "352  https://www.ncbi.nlm.nih.gov/books/NBK548593/,...   \n",
       "353  https://www.ncbi.nlm.nih.gov/books/NBK548299/,...   \n",
       "354  https://onlinelibrary.wiley.com/doi/full/10.10...   \n",
       "355                                                NaN   \n",
       "356                                                NaN   \n",
       "\n",
       "                                   standardized_smiles  \n",
       "0    CC[C@H]1[C@@H](O)[C@@H]2[C@H](CC[C@]3(C)[C@@H]...  \n",
       "1    C=CC(=O)N1CCC(CN=c2[nH]cnc(N)c2-c2ccc(Oc3ccccc...  \n",
       "2    C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)...  \n",
       "3    C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)...  \n",
       "4    C[C@H]1CN(C2COC2)CCN1c1ccc(=Nc2cc(-c3ccnc(N4CC...  \n",
       "..                                                 ...  \n",
       "352  CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@...  \n",
       "353  CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)NC4C[C@@H](O)[C...  \n",
       "354  C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)...  \n",
       "355  C[C@H]1COc2c(C3(N)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23  \n",
       "356  CC(C)(ON=C(C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]...  \n",
       "\n",
       "[357 rows x 18 columns]"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.read_csv(\"filtered.csv\")\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "7c360f2d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.microsoft.datawrangler.viewer.v0+json": {
       "columns": [
        {
         "name": "index",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "compound_name",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "is_dili",
         "rawType": "int64",
         "type": "integer"
        },
        {
         "name": "Literature Search",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "claude__DILI Status",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "gpt5__DILI in clinic?",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "perplexity__DILI in Clinical Trials",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "grok__Clinical DILI Reported",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "futurehouse_labels",
         "rawType": "float64",
         "type": "float"
        },
        {
         "name": "claude__Unnamed: 2",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "gpt5__One-line evidence",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "gpt5__Key source(s)",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "perplexity__Details",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "pubchem_smiles",
         "rawType": "object",
         "type": "string"
        },
        {
         "name": "dili_case_check Reasoning [Reasoning for the match decision]",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "dili_case_check Citations [Source citations for this match]",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "URL [Entity URL]",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "   ",
         "rawType": "object",
         "type": "unknown"
        },
        {
         "name": "smiles",
         "rawType": "object",
         "type": "string"
        }
       ],
       "ref": "b6e5dd89-c0da-40ac-b68a-7ac8c9a8b211",
       "rows": [
        [
         "0",
         "Ocaliva",
         "1",
         "True",
         null,
         null,
         null,
         "1.0",
         "1.0",
         null,
         null,
         null,
         null,
         "CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCC(=O)O)C)C)O",
         null,
         null,
         null,
         null,
         "CC[C@H]1[C@@H](O)[C@@H]2[C@H](CC[C@]3(C)[C@@H]([C@H](C)CCC(=O)O)CC[C@@H]23)[C@@]2(C)CC[C@@H](O)C[C@@H]12"
        ],
        [
         "1",
         "Evobrutinib",
         "1",
         "True",
         "1.0",
         "1.0",
         "1.0",
         "1.0",
         null,
         "2 MS patients developed liver injury in Phase III EVOLUTION trial; patients asymptomatic, liver enzymes normalized after discontinuation",
         "Trials saw ALT/AST ↑ and Hy’s-law–type cases; LFT monitoring.",
         "(The Lancet)",
         "FDA imposed partial clinical hold after liver toxicity cases in Phase III BTK-inhibitor trials.",
         "C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N",
         null,
         null,
         null,
         null,
         "C=CC(=O)N1CCC(CN=c2[nH]cnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1"
        ],
        [
         "2",
         "Orelabrutinib",
         "1",
         "True",
         "1.0",
         "1.0",
         "1.0",
         "1.0",
         null,
         "Drug-related cases of liver injury reported",
         "BTK inhibitor class has reported DILI; monitoring advised; specific orelabrutinib DILI is rare.",
         "(PMC)",
         "Partial clinical hold in December 2022 due to drug-related liver injury cases.",
         "C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C(C=C3)OC4=CC=CC=C4",
         null,
         null,
         null,
         null,
         "C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)cc3)n2)CC1"
        ],
        [
         "3",
         "Tolebrutinib",
         "1",
         "True",
         "1.0",
         "1.0",
         "1.0",
         "1.0",
         null,
         "Liver toxicity issues; one patient required liver transplant and died from complications",
         "MS program experienced serious liver injury cases/partial holds.",
         "(Alyftrek HCP)",
         "Partial Phase III hold following reversible DILI cases in trials.",
         "C=CC(=O)N1CCC[C@H](C1)N2C3=C(C(=NC=C3)N)N(C2=O)C4=CC=C(C=C4)OC5=CC=CC=C5",
         null,
         null,
         null,
         null,
         "C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)cc3)c3c(=N)[nH]ccc32)C1"
        ],
        [
         "4",
         "Fenebrutinib",
         "1",
         "True",
         null,
         "1.0",
         "1.0",
         "1.0",
         null,
         null,
         "Trials reported liver enzyme elevations (class effect; monitor).",
         "(Gene)",
         "Hepatic transaminase grade ≥2 elevations more frequent (8.2% vs 2.8% placebo) in relapsing MS studies.",
         "C[C@H]1CN(CCN1C2=CN=C(C=C2)NC3=CC(=CN(C3=O)C)C4=C(C(=NC=C4)N5CCN6C7=C(CC(C7)(C)C)C=C6C5=O)CO)C8COC8",
         null,
         null,
         null,
         null,
         "C[C@H]1CN(C2COC2)CCN1c1ccc(=Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)[nH]c1"
        ],
        [
         "5",
         "Azelaprag",
         "1",
         "True",
         "1.0",
         "1.0",
         "1.0",
         null,
         null,
         "11 individuals in treatment groups experienced elevated liver enzyme levels in STRIDES Phase I trial",
         "Phase 2b/3 halted for transaminase elevations (liver safety signal).",
         "(FDA Access Data)",
         "STRIDES Phase I trial discontinued after 11 participants developed elevated liver enzyme levels.",
         "CC1=CC(=CN=C1)C2=NN=C(N2C3=C(C=CC=C3OC)OC)NS(=O)(=O)[C@@H](C)[C@H](C)C4=NC=C(C=N4)C",
         null,
         null,
         null,
         null,
         "COc1cccc(OC)c1-n1c(-c2cncc(C)c2)n[nH]c1=NS(=O)(=O)[C@@H](C)C(C)c1ncc(C)cn1"
        ],
        [
         "6",
         "TNG348",
         "1",
         "True",
         "1.0",
         "1.0",
         "1.0",
         null,
         null,
         "Grade 3 and life-threatening grade 4 liver function abnormalities after 8 weeks of treatment in Phase I/II study",
         "Trial discontinued due to liver toxicity/clinical hold.",
         "(PMC)",
         "Development halted for grade 3–4 liver function abnormalities in Phase I participants beyond 8 weeks.",
         "CN1C=C(N=C1C2=CC=C(C=C2)CN3C4=NC(=NC=C4N(C3=N)CC(F)(F)F)C5=C(N=CN=C5OC)C6CC6)C(F)(F)F",
         null,
         null,
         null,
         null,
         "COc1ncnc(C2CC2)c1-c1ncc2c(n1)n(Cc1ccc(-c3nc(C(F)(F)F)cn3C)cc1)c(=N)n2CC(F)(F)F"
        ],
        [
         "7",
         "Danuglipron",
         "1",
         "True",
         null,
         "1.0",
         "1.0",
         null,
         null,
         null,
         "Pfizer discontinued oral program citing potential DILI after LFT elevations.",
         "(U.S. Food and Drug Administration)",
         "Discontinued after one patient in Phase I experienced liver injury; enzymes recovered on discontinuation.",
         "C1CO[C@@H]1CN2C3=C(C=CC(=C3)C(=O)O)N=C2CN4CCC(CC4)C5=NC(=CC=C5)OCC6=C(C=C(C=C6)C#N)F",
         null,
         null,
         null,
         null,
         "N#Cc1ccc(COc2cccc(C3CCN(Cc4nc5ccc(C(=O)O)cc5n4C[C@@H]4CCO4)CC3)n2)c(F)c1"
        ],
        [
         "8",
         "Lotiglipron",
         "1",
         "True",
         null,
         "1.0",
         "1.0",
         null,
         null,
         null,
         "Pfizer terminated program for elevated transaminases/potential liver toxicity.",
         "(U.S. Food and Drug Administration)",
         "Development withdrawn in June 2023 after early trials showed elevated liver enzymes indicating hepatotoxicity.",
         "C[C@@]1(OC2=CC=CC(=C2O1)C3CCN(CC3)CC4=NC5=C(N4C[C@@H]6CCO6)C=C(C=C5)C(=O)O)C7=NC=C(C=C7)Cl",
         null,
         null,
         null,
         null,
         "C[C@]1(c2ccc(Cl)cn2)Oc2cccc(C3CCN(Cc4nc5ccc(C(=O)O)cc5n4C[C@@H]4CCO4)CC3)c2O1"
        ],
        [
         "9",
         "TAK-994",
         "1",
         "True",
         null,
         "1.0",
         "1.0",
         null,
         null,
         null,
         "Program stopped for hepatotoxicity; partial clinical hold reported.",
         "(RAPT Investors)",
         "Withdrawn from Phase II due to severe DILI; 3 patients met Hy’s Law criteria.",
         "CC(C)(C(=O)N1CC[C@@H]([C@@H]1CC2=C(C(=CC=C2)C3=CC(=CC(=C3)F)F)F)NS(=O)(=O)C)O.O",
         null,
         null,
         null,
         null,
         "CC(C)(O)C(=O)N1CC[C@H](NS(C)(=O)=O)[C@@H]1Cc1cccc(-c2cc(F)cc(F)c2)c1F"
        ],
        [
         "10",
         "Mitapivat",
         "1",
         "True",
         null,
         "1.0",
         null,
         null,
         null,
         null,
         "Label: LFT monitoring in long-term therapy; transaminase elevations noted.",
         "(FirstWord Pharma)",
         null,
         "C1CC1CN2CCN(CC2)C(=O)C3=CC=C(C=C3)NS(=O)(=O)C4=CC=CC5=C4N=CC=C5",
         null,
         null,
         null,
         null,
         "O=C(c1ccc(NS(=O)(=O)c2cccc3cccnc23)cc1)N1CCN(CC2CC2)CC1"
        ],
        [
         "11",
         "Zelnecirnon",
         "1",
         "True",
         null,
         "1.0",
         null,
         null,
         null,
         null,
         "Program discontinued after severe liver injury case/clinical hold.",
         "(FDA Access Data)",
         null,
         "CC1=C(C(=NC(=N1)N2CC(C2)[C@H]3CCCN(C3)C4CC(C4)(C)C(=O)O)N[C@H](C)C5=C(C=C(C=C5)Cl)Cl)Cl",
         null,
         null,
         null,
         null,
         "Cc1[nH]c(N2CC([C@H]3CCCN(C4CC(C)(C(=O)O)C4)C3)C2)nc(=N[C@H](C)c2ccc(Cl)cc2Cl)c1Cl"
        ],
        [
         "12",
         "Icovamenib",
         "1",
         "True",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "C=CC(=O)N[C@@H]1CCCN(C1)CC2=CC(=NC=C2)C(=O)NC3=CC=C(C=C3)C4=CC5=C(N4)N=CN=C5N6CCOCC6",
         null,
         null,
         null,
         null,
         "C=CC(=O)N[C@@H]1CCCN(Cc2ccnc(C(=O)Nc3ccc(-c4cc5c(N6CCOCC6)ncnc5[nH]4)cc3)c2)C1"
        ],
        [
         "13",
         "Elafibranor",
         "1",
         null,
         null,
         "1.0",
         "1.0",
         "1.0",
         "1.0",
         null,
         "PBC label includes liver test monitoring/impairment guidance (no boxed DILI).",
         "(Ohtuvayre HCP)",
         "DILI in three patients (one at 80 mg, two at 1.5× dose); one presented as autoimmune-like hepatitis.",
         "CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)/C=C/C(=O)C2=CC=C(C=C2)SC",
         null,
         null,
         null,
         null,
         "CSc1ccc(C(=O)/C=C/c2cc(C)c(OC(C)(C)C(=O)O)c(C)c2)cc1"
        ],
        [
         "14",
         "Momelotinib",
         "1",
         null,
         null,
         "1.0",
         "1.0",
         "1.0",
         "1.0",
         null,
         "Label: “OJJAARA can cause hepatotoxicity;” baseline & monthly LFTs first 6 mo.",
         "(FDA Access Data, ojjaarahcp.com)",
         "Grade 3–4 ALT elevations in 4%; AST/ALP in 2% each; grade 1–2 increases also reported.",
         "C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N",
         null,
         null,
         null,
         null,
         "N#CCNC(=O)c1ccc(-c2cc[nH]c(=Nc3ccc(N4CCOCC4)cc3)n2)cc1"
        ],
        [
         "15",
         "Resmetirom",
         "1",
         null,
         null,
         "1.0",
         "1.0",
         "1.0",
         "1.0",
         null,
         "Label/HCP: explicit Hepatotoxicity warning; monitor; 1 notable case in trials.",
         "(FDA Access Data, Rezdiffra® (resmetirom) HCP Website)",
         "Three of four reviewed cases probable DILI; one Hy’s Law case with autoimmune-like hepatitis phenotype.",
         "CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl",
         null,
         null,
         null,
         null,
         "CC(C)c1cc(Oc2c(Cl)cc(-n3nc(C#N)c(=O)[nH]c3=O)cc2Cl)n[nH]c1=O"
        ],
        [
         "16",
         "Vadadustat",
         "1",
         null,
         null,
         "1.0",
         "1.0",
         "1.0",
         "1.0",
         null,
         "Label: monitor ALT/AST & bilirubin; not recommended in cirrhosis/acute liver disease.",
         "(FDA Access Data)",
         "Several probable DILI cases, including one Hy’s Law–type event in premarketing application.",
         "C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O",
         null,
         null,
         null,
         null,
         "O=C(O)CNC(=O)c1ncc(-c2cccc(Cl)c2)cc1O"
        ],
        [
         "17",
         "Tovorafenib",
         "1",
         null,
         null,
         "1.0",
         "1.0",
         null,
         "1.0",
         null,
         "Label: transaminase elevations; LFT monitoring guidance.",
         "(U.S. Food and Drug Administration)",
         "Serum enzyme elevations and liver injury likely due to direct BRAF/MAPK pathway–mediated toxicity.",
         "C[C@H](C1=NC=C(S1)C(=O)NC2=NC=C(C(=C2)C(F)(F)F)Cl)NC(=O)C3=C(C(=NC=N3)N)Cl",
         null,
         null,
         null,
         null,
         "CC(NC(=O)c1[nH]cnc(=N)c1Cl)c1ncc(C(=O)N=c2cc(C(F)(F)F)c(Cl)c[nH]2)s1"
        ],
        [
         "18",
         "Seladelpar",
         "0",
         null,
         null,
         "1.0",
         null,
         null,
         "1.0",
         null,
         "HCP/label: dose-related transaminase increases at high doses; monitor (10 mg label dose).",
         "(livdelzihcp.com, Gilead)",
         null,
         "CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC(=C(C=C2)OCC(=O)O)C",
         null,
         null,
         null,
         null,
         "CCO[C@H](COc1ccc(C(F)(F)F)cc1)CSc1ccc(OCC(=O)O)c(C)c1"
        ],
        [
         "19",
         "Elacestrant",
         "0",
         null,
         null,
         null,
         null,
         null,
         "1.0",
         null,
         null,
         null,
         null,
         "CCNCCC1=CC=C(C=C1)CN(CC)C2=C(C=CC(=C2)OC)[C@@H]3CCC4=C(C3)C=CC(=C4)O",
         null,
         null,
         null,
         null,
         "CCNCCc1ccc(CN(CC)c2cc(OC)ccc2[C@@H]2CCc3cc(O)ccc3C2)cc1"
        ],
        [
         "20",
         "Danicopan",
         "0",
         null,
         null,
         "1.0",
         "1.0",
         null,
         null,
         null,
         "Label/EMA: transaminase/bilirubin increases monitored; LFT monitoring described in review.",
         "(European Medicines Agency (EMA), FDA Access Data)",
         "Two subjects with probable DILI; ten additional suspected cases deemed unlikely.",
         "CC1=NC=C(C=N1)C2=CC3=C(C=C2)N(N=C3C(=O)C)CC(=O)N4C[C@@H](C[C@H]4C(=O)NC5=NC(=CC=C5)Br)F",
         null,
         null,
         null,
         null,
         "CC(=O)c1nn(CC(=O)N2C[C@H](F)CC2C(=O)N=c2cccc(Br)[nH]2)c2ccc(-c3cnc(C)nc3)cc12"
        ],
        [
         "21",
         "Ensartinib",
         "0",
         null,
         null,
         "1.0",
         "1.0",
         null,
         null,
         null,
         "Label & LiverTox recommend baseline/frequent LFT monitoring (ALK TKI).",
         "(FDA Access Data, NCBI)",
         "ALK-inhibitor–associated hepatotoxicity; severe hyperbilirubinemia requiring artificial liver support reported.",
         "C[C@@H]1CN(C[C@@H](N1)C)C(=O)C2=CC=C(C=C2)NC(=O)C3=NN=C(C(=C3)O[C@H](C)C4=C(C=CC(=C4Cl)F)Cl)N",
         null,
         null,
         null,
         null,
         "C[C@@H]1CN(C(=O)c2ccc(NC(=O)c3cc(O[C@H](C)c4c(Cl)ccc(F)c4Cl)c(=N)[nH]n3)cc2)C[C@H](C)N1"
        ],
        [
         "22",
         "Pirtobrutinib",
         "0",
         null,
         null,
         "1.0",
         "1.0",
         null,
         null,
         null,
         "Label warns “hepatotoxicity (including DILI)” and to monitor LFTs.",
         null,
         "Severe hepatotoxicity with Hy’s Law cases; FDA label includes hepatotoxicity warning.",
         "C[C@@H](C(F)(F)F)N1C(=C(C(=N1)C2=CC=C(C=C2)CNC(=O)C3=C(C=CC(=C3)F)OC)C(=O)N)N",
         null,
         null,
         null,
         null,
         "COc1ccc(F)cc1C(=O)NCc1ccc(-c2[nH]n([C@@H](C)C(F)(F)F)c(=N)c2C(N)=O)cc1"
        ],
        [
         "23",
         "Quizartinib",
         "0",
         null,
         null,
         "1.0",
         "1.0",
         null,
         null,
         null,
         "LFT elevations reported; LiverTox: rare acute injury/“hepatic failure” events attributed to other causes.",
         "(NCBI)",
         "High rate of liver enzyme elevations during therapy, comparable to control arms.",
         "CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3",
         null,
         null,
         null,
         null,
         "CC(C)(C)c1cc(=NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)[nH]o1"
        ],
        [
         "24",
         "Ritlecitinib",
         "0",
         null,
         null,
         "1.0",
         "1.0",
         null,
         null,
         null,
         "Label: ALT/AST ≥5×ULN occurred; investigate/interrupt if DILI suspected.",
         "(FDA Access Data, litfulo.pfizerpro.com)",
         "1–3% incidence of aminotransferase elevations; label warns of DILI risk.",
         "C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3",
         null,
         null,
         null,
         null,
         "C=CC(=O)N1C[C@H](N=c2[nH]cnc3[nH]ccc23)CC[C@@H]1C"
        ],
        [
         "25",
         "Ceftobiprole medocaril",
         "0",
         null,
         null,
         "1.0",
         null,
         null,
         null,
         null,
         "Label: “hepatic enzyme increased / bilirubin increased” among common AEs.",
         "(FDA Access Data)",
         null,
         "CC1=C(OC(=O)O1)COC(=O)N2CC[C@H](C2)N3CC/C(=C\\C4=C(N5[C@@H]([C@@H](C5=O)NC(=O)/C(=N\\O)/C6=NSC(=N6)N)SC4)C(=O)O)/C3=O",
         null,
         null,
         null,
         null,
         "Cc1oc(=O)oc1COC(=O)N1CC[C@@H](n2ccc(C=C3CS[C@@H]4C(NC(=O)C(=NO)c5nc(=N)s[nH]5)C(=O)N4C3C(=O)O)c2O)C1"
        ],
        [
         "26",
         "Inavolisib",
         "0",
         null,
         null,
         "1.0",
         null,
         null,
         null,
         null,
         "Label/refs: transaminase elevations; routine monitoring in oncology regimens.",
         "(FDA Access Data, NCBI)",
         null,
         "C[C@@H](C(=O)N)NC1=CC2=C(C=C1)C3=NC(=CN3CCO2)N4[C@@H](COC4=O)C(F)F",
         null,
         null,
         null,
         null,
         "CC(Nc1ccc2c(c1)OCCn1cc(N3C(=O)OC[C@H]3C(F)F)nc1-2)C(N)=O"
        ],
        [
         "27",
         "Palovarotene",
         "0",
         null,
         null,
         "1.0",
         null,
         null,
         null,
         null,
         "Label notes transaminase elevations/“hepatic cytolysis;” monitor.",
         "(jaypirca.lilly.com)",
         null,
         "CC1(CCC(C2=C1C=C(C(=C2)/C=C/C3=CC=C(C=C3)C(=O)O)CN4C=CC=N4)(C)C)C",
         null,
         null,
         null,
         null,
         "CC1(C)CCC(C)(C)c2cc(Cn3cccn3)c(/C=C/c3ccc(C(=O)O)cc3)cc21"
        ],
        [
         "28",
         "Revumenib",
         "0",
         null,
         null,
         "1.0",
         null,
         null,
         null,
         null,
         "Label/refs: LFT elevations monitored in trials (menin inhibitor class).",
         "(FDA Access Data)",
         null,
         "CCN(C(C)C)C(=O)C1=C(C=CC(=C1)F)OC2=CN=CN=C2N3CC4(C3)CCN(CC4)CC5CCC(CC5)NS(=O)(=O)CC",
         null,
         null,
         null,
         null,
         "CCN(C(=O)c1cc(F)ccc1Oc1cncnc1N1CC2(CCN(CC3CCC(NS(=O)(=O)CC)CC3)CC2)C1)C(C)C"
        ],
        [
         "29",
         "Acoramidis",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC1=C(C(=NN1)C)CCCOC2=C(C=CC(=C2)C(=O)O)F",
         null,
         null,
         null,
         null,
         "Cc1n[nH]c(C)c1CCCOc1cc(C(=O)O)ccc1F"
        ],
        [
         "30",
         "Arimoclomol",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "C1CCN(CC1)C[C@H](CON=C(C2=C[N+](=CC=C2)[O-])Cl)O",
         null,
         null,
         null,
         null,
         "[O-][n+]1cccc(C(Cl)=NOC[C@H](O)CN2CCCCC2)c1"
        ],
        [
         "31",
         "Bexagliflozin",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl",
         null,
         null,
         null,
         null,
         "OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O"
        ],
        [
         "32",
         "Crinecerfont",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC1=C(C=C(C=C1)[C@H](CC2CC2)N(CC#C)C3=NC(=C(S3)C)C4=C(C=C(C(=C4)C)OC)Cl)F",
         null,
         null,
         null,
         null,
         "C#CCN(c1nc(-c2cc(C)c(OC)cc2Cl)c(C)s1)[C@@H](CC1CC1)c1ccc(C)c(F)c1"
        ],
        [
         "33",
         "Ensifentrine",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC1=CC(=C(C(=C1)C)N=C2C=C3C4=CC(=C(C=C4CCN3C(=O)N2CCNC(=O)N)OC)OC)C",
         null,
         null,
         null,
         null,
         "COc1cc2c(cc1OC)-c1cc(=Nc3c(C)cc(C)cc3C)n(CCNC(N)=O)c(=O)n1CC2"
        ],
        [
         "34",
         "Gepirone",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3=NC=CC=N3)C",
         null,
         null,
         null,
         null,
         "CC1(C)CC(=O)N(CCCCN2CCN(c3ncccn3)CC2)C(=O)C1"
        ],
        [
         "35",
         "Givinostat",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO",
         null,
         null,
         null,
         null,
         "CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(C(O)=NO)cc3)ccc2c1"
        ],
        [
         "36",
         "Iptacopan",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CCO[C@H]1CCN([C@@H](C1)C2=CC=C(C=C2)C(=O)O)CC3=C(C=C(C4=C3C=CN4)C)OC",
         null,
         null,
         null,
         null,
         "CCO[C@H]1CCN(Cc2c(OC)cc(C)c3[nH]ccc23)C(c2ccc(C(=O)O)cc2)C1"
        ],
        [
         "37",
         "Landiolol",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC1(OC[C@H](O1)COC(=O)CCC2=CC=C(C=C2)OC[C@H](CNCCNC(=O)N3CCOCC3)O)C",
         null,
         null,
         null,
         null,
         "CC1(C)OC[C@@H](COC(=O)CCc2ccc(OC[C@@H](O)CNCCNC(=O)N3CCOCC3)cc2)O1"
        ],
        [
         "38",
         "Levacetylleucine",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC(C)C[C@@H](C(=O)O)NC(=O)C",
         null,
         null,
         null,
         null,
         "CC(=O)NC(CC(C)C)C(=O)O"
        ],
        [
         "39",
         "Lotilaner",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC1=C(SC(=C1)C2=NO[C@@](C2)(C3=CC(=C(C(=C3)Cl)Cl)Cl)C(F)(F)F)C(=O)NCC(=O)NCC(F)(F)F",
         null,
         null,
         null,
         null,
         "Cc1cc(C2=NO[C@@](c3cc(Cl)c(Cl)c(Cl)c3)(C(F)(F)F)C2)sc1C(=O)NCC(=O)NCC(F)(F)F"
        ],
        [
         "40",
         "Sulopenem etzadroxil",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CCC(CC)C(=O)OCOC(=O)C1=C(S[C@H]2N1C(=O)[C@@H]2[C@@H](C)O)S[C@H]3CC[S@@](=O)C3",
         null,
         null,
         null,
         null,
         "CCC(CC)C(=O)OCOC(=O)C1=C(S[C@H]2CC[S@@+]([O-])C2)S[C@@H]2C([C@@H](C)O)C(=O)N12"
        ],
        [
         "41",
         "Tezacaftor",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC(C)(CO)C1=CC2=CC(=C(C=C2N1C[C@H](CO)O)F)NC(=O)C3(CC3)C4=CC5=C(C=C4)OC(O5)(F)F",
         null,
         null,
         null,
         null,
         "CC(C)(CO)c1cc2cc(NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c(F)cc2n1C[C@@H](O)CO"
        ],
        [
         "42",
         "Vanzacaftor",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC1(C[C@@H]2CCCNC3=NC(=CC=C3)S(=O)(=O)NC(=O)C4=C(N1C2)N=C(C=C4)N5C=CC(=N5)OCCC6C7(C68CC8)CC7)C",
         null,
         null,
         null,
         null,
         "CC1(C)C[C@@H]2CCCNc3cccc(n3)S(=O)(=O)NC(=O)c3ccc(-n4ccc(OCCC5C6(CC6)C56CC6)n4)nc3N1C2"
        ],
        [
         "43",
         "Cefcapene pivoxil",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CC/C=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)OCOC(=O)C(C)(C)C",
         "No clear, documented case of drug-induced liver injury specifically attributed to cefcapene pivoxil was found in the provided sources.",
         null,
         "amjcaserep.com/abstract/full/idArt/928587",
         null,
         "CCCC(C(=O)N=C1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(COC(N)=O)CSC12)c1csc(=N)[nH]1"
        ],
        [
         "44",
         "Ornithine phenylacetate",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "C1=CC=C(C=C1)CC(=O)O.C(C[C@@H](C(=O)O)N)CN",
         "Clinical safety/PK study (PMC5826861) and the randomized phase 2b trial report no safety signals or evidence that OP causes drug-induced liver injury; adverse event rates were similar to placebo.",
         null,
         "cghjournal.org/article/s1542-3565(20)31432-4/fulltext",
         null,
         "NCCCC(N)C(=O)O"
        ],
        [
         "45",
         "S-Adenosylmethionine",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "C[S+](CC[C@@H](C(=O)[O-])N)C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=NC3=C(N=CN=C32)N)O)O",
         "Available peer-reviewed reviews and curated drug/chemical databases describe SAMe as a hepatoprotective/endogenous agent used therapeutically in liver disease and for prevention/management of chemotherapy-associated liver injury; they do not identify SAMe as a causative agent of DILI.",
         null,
         "pubchem.ncbi.nlm.nih.gov/compound/S-adenosylmethionine",
         null,
         "C[S+](CCC(N)C(=O)[O-])C[C@H]1O[C@@H](n2cnc3c(=N)[nH]cnc32)[C@H](O)[C@@H]1O"
        ],
        [
         "46",
         "Pipemidic acid",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "CCN1C=C(C(=O)C2=CN=C(N=C21)N3CCNCC3)C(=O)O",
         "No clear primary clinical case report or regulatory/registry entry identifying pipemidic acid as a confirmed cause of drug-induced liver injury was found in the provided sources. Some secondary sources note possible effects on liver function and NCATS lists contraindication in severe hepatic insufficiency, but that is not the same as documented drug-induced liver injury cases.",
         null,
         "drugs.ncats.io/drug/LT12J5HVR8",
         null,
         "CCn1cc(C(=O)O)c(=O)c2cnc(N3CCNCC3)nc21"
        ],
        [
         "47",
         "Ceftobiprole",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "C1CNC[C@@H]1N2CC/C(=C\\C3=C(N4[C@@H]([C@@H](C4=O)NC(=O)/C(=N\\O)/C5=NSC(=N5)N)SC3)C(=O)O)/C2=O",
         "Ceftobiprole is not established as a DILI-positive compound in clinical trials or regulatory review. Trial and FDA data found no Hy's law cases attributable to the drug and concluded an association with clinically significant DILI is unlikely; real-world studies report increased liver-related AEs in patients with preexisting hepatic impairment or immunocompromise but found no new DILI safety signal.",
         "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/218275Orig1s000IntegratedR.pdf, https://pmc.ncbi.nlm.nih.gov/articles/PMC6755345/",
         "accessdata.fda.gov/drugsatfda_docs/nda/2024/218275Orig1s000IntegratedR.pdf",
         null,
         "N=c1[nH]c(C(=NO)C(=O)NC2C(=O)N3C(C(=O)O)=C(Cc4ccn([C@@H]5CCNC5)c4O)CS[C@H]23)ns1"
        ],
        [
         "48",
         "Norepinephrine",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "C1=CC(=C(C=C1[C@H](CN)O)O)O",
         "The FDA DILIst dataset does not classify Norepinephrine as a DILI-positive agent. While experimental studies show potential hepatotoxicity under specific conditions, clinical DILI attribution is not established.",
         "https://pubchem.ncbi.nlm.nih.gov/compound/Norepinephrine-hydrochloride",
         "fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset",
         null,
         "NC[C@H](O)c1ccc(O)c(O)c1"
        ],
        [
         "49",
         "Tebipenem",
         "0",
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         null,
         "C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1SC3CN(C3)C4=NCCS4)C(=O)O)[C@@H](C)O",
         "Clinical trials reported only rare, mild ALT/AST elevations (<=1%) and explicitly stated that no patients met Hy's law criteria for drug-induced liver injury. No clinical DILI cases meeting Hy's law or severe DILI have been reported in available human studies.",
         "https://www.nejm.org/doi/full/10.1056/NEJMoa2105462",
         "nejm.org/doi/full/10.1056/NEJMoa2105462",
         null,
         "CC1=C(SC2CN(C3=NCCS3)C2)C(C(=O)O)N2C(=O)C([C@@H](C)O)[C@@H]12"
        ]
       ],
       "shape": {
        "columns": 18,
        "rows": 357
       }
      },
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>compound_name</th>\n",
       "      <th>is_dili</th>\n",
       "      <th>Literature Search</th>\n",
       "      <th>claude__DILI Status</th>\n",
       "      <th>gpt5__DILI in clinic?</th>\n",
       "      <th>perplexity__DILI in Clinical Trials</th>\n",
       "      <th>grok__Clinical DILI Reported</th>\n",
       "      <th>futurehouse_labels</th>\n",
       "      <th>claude__Unnamed: 2</th>\n",
       "      <th>gpt5__One-line evidence</th>\n",
       "      <th>gpt5__Key source(s)</th>\n",
       "      <th>perplexity__Details</th>\n",
       "      <th>pubchem_smiles</th>\n",
       "      <th>dili_case_check Reasoning [Reasoning for the match decision]</th>\n",
       "      <th>dili_case_check Citations [Source citations for this match]</th>\n",
       "      <th>URL [Entity URL]</th>\n",
       "      <th></th>\n",
       "      <th>smiles</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Ocaliva</td>\n",
       "      <td>1</td>\n",
       "      <td>True</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CC[C@H]1[C@@H](O)[C@@H]2[C@H](CC[C@]3(C)[C@@H]...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Evobrutinib</td>\n",
       "      <td>1</td>\n",
       "      <td>True</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>2 MS patients developed liver injury in Phase ...</td>\n",
       "      <td>Trials saw ALT/AST ↑ and Hy’s-law–type cases; ...</td>\n",
       "      <td>(The Lancet)</td>\n",
       "      <td>FDA imposed partial clinical hold after liver ...</td>\n",
       "      <td>C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)O...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>C=CC(=O)N1CCC(CN=c2[nH]cnc(N)c2-c2ccc(Oc3ccccc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Orelabrutinib</td>\n",
       "      <td>1</td>\n",
       "      <td>True</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Drug-related cases of liver injury reported</td>\n",
       "      <td>BTK inhibitor class has reported DILI; monitor...</td>\n",
       "      <td>(PMC)</td>\n",
       "      <td>Partial clinical hold in December 2022 due to ...</td>\n",
       "      <td>C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Tolebrutinib</td>\n",
       "      <td>1</td>\n",
       "      <td>True</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Liver toxicity issues; one patient required li...</td>\n",
       "      <td>MS program experienced serious liver injury ca...</td>\n",
       "      <td>(Alyftrek HCP)</td>\n",
       "      <td>Partial Phase III hold following reversible DI...</td>\n",
       "      <td>C=CC(=O)N1CCC[C@H](C1)N2C3=C(C(=NC=C3)N)N(C2=O...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Fenebrutinib</td>\n",
       "      <td>1</td>\n",
       "      <td>True</td>\n",
       "      <td>NaN</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>1.0</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Trials reported liver enzyme elevations (class...</td>\n",
       "      <td>(Gene)</td>\n",
       "      <td>Hepatic transaminase grade ≥2 elevations more ...</td>\n",
       "      <td>C[C@H]1CN(CCN1C2=CN=C(C=C2)NC3=CC(=CN(C3=O)C)C...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>C[C@H]1CN(C2COC2)CCN1c1ccc(=Nc2cc(-c3ccnc(N4CC...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>352</th>\n",
       "      <td>Pergolide</td>\n",
       "      <td>1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC</td>\n",
       "      <td>Multiple authoritative sources, including Live...</td>\n",
       "      <td>https://pubchem.ncbi.nlm.nih.gov/compound/Perg...</td>\n",
       "      <td>ncbi.nlm.nih.gov/books/NBK548593</td>\n",
       "      <td>https://www.ncbi.nlm.nih.gov/books/NBK548593/,...</td>\n",
       "      <td>CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>353</th>\n",
       "      <td>Anidulafungin</td>\n",
       "      <td>1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C...</td>\n",
       "      <td>Anidulafungin has documented reports/signals o...</td>\n",
       "      <td>https://www.sciencedirect.com/topics/biochemis...</td>\n",
       "      <td>frontiersin.org/journals/pharmacology/articles...</td>\n",
       "      <td>https://www.ncbi.nlm.nih.gov/books/NBK548299/,...</td>\n",
       "      <td>CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)NC4C[C@@H](O)[C...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>354</th>\n",
       "      <td>Ibrutinib</td>\n",
       "      <td>1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>C=CC(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=C...</td>\n",
       "      <td>Multiple sources, including LiverTox and case ...</td>\n",
       "      <td>https://journals.lww.com/ajg/fulltext/2017/100...</td>\n",
       "      <td>ncbi.nlm.nih.gov/books/NBK548449</td>\n",
       "      <td>https://onlinelibrary.wiley.com/doi/full/10.10...</td>\n",
       "      <td>C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>355</th>\n",
       "      <td>Pazufloxacin</td>\n",
       "      <td>1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C...</td>\n",
       "      <td>Pazufloxacin is listed in the FDA Drug-Induced...</td>\n",
       "      <td>https://pmc.ncbi.nlm.nih.gov/articles/PMC61815...</td>\n",
       "      <td>fda.gov/science-research/liver-toxicity-knowle...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>C[C@H]1COc2c(C3(N)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>356</th>\n",
       "      <td>Cefiderocol</td>\n",
       "      <td>1</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2...</td>\n",
       "      <td>Cefiderocol has reported transient aminotransf...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ncbi.nlm.nih.gov/books/NBK547862</td>\n",
       "      <td>NaN</td>\n",
       "      <td>CC(C)(ON=C(C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>357 rows × 18 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     compound_name  is_dili Literature Search  claude__DILI Status  \\\n",
       "0          Ocaliva        1              True                  NaN   \n",
       "1      Evobrutinib        1              True                  1.0   \n",
       "2    Orelabrutinib        1              True                  1.0   \n",
       "3     Tolebrutinib        1              True                  1.0   \n",
       "4     Fenebrutinib        1              True                  NaN   \n",
       "..             ...      ...               ...                  ...   \n",
       "352      Pergolide        1               NaN                  NaN   \n",
       "353  Anidulafungin        1               NaN                  NaN   \n",
       "354      Ibrutinib        1               NaN                  NaN   \n",
       "355   Pazufloxacin        1               NaN                  NaN   \n",
       "356    Cefiderocol        1               NaN                  NaN   \n",
       "\n",
       "     gpt5__DILI in clinic?  perplexity__DILI in Clinical Trials  \\\n",
       "0                      NaN                                  NaN   \n",
       "1                      1.0                                  1.0   \n",
       "2                      1.0                                  1.0   \n",
       "3                      1.0                                  1.0   \n",
       "4                      1.0                                  1.0   \n",
       "..                     ...                                  ...   \n",
       "352                    NaN                                  NaN   \n",
       "353                    NaN                                  NaN   \n",
       "354                    NaN                                  NaN   \n",
       "355                    NaN                                  NaN   \n",
       "356                    NaN                                  NaN   \n",
       "\n",
       "     grok__Clinical DILI Reported  futurehouse_labels  \\\n",
       "0                             1.0                 1.0   \n",
       "1                             1.0                 NaN   \n",
       "2                             1.0                 NaN   \n",
       "3                             1.0                 NaN   \n",
       "4                             1.0                 NaN   \n",
       "..                            ...                 ...   \n",
       "352                           NaN                 NaN   \n",
       "353                           NaN                 NaN   \n",
       "354                           NaN                 NaN   \n",
       "355                           NaN                 NaN   \n",
       "356                           NaN                 NaN   \n",
       "\n",
       "                                    claude__Unnamed: 2  \\\n",
       "0                                                  NaN   \n",
       "1    2 MS patients developed liver injury in Phase ...   \n",
       "2          Drug-related cases of liver injury reported   \n",
       "3    Liver toxicity issues; one patient required li...   \n",
       "4                                                  NaN   \n",
       "..                                                 ...   \n",
       "352                                                NaN   \n",
       "353                                                NaN   \n",
       "354                                                NaN   \n",
       "355                                                NaN   \n",
       "356                                                NaN   \n",
       "\n",
       "                               gpt5__One-line evidence gpt5__Key source(s)  \\\n",
       "0                                                  NaN                 NaN   \n",
       "1    Trials saw ALT/AST ↑ and Hy’s-law–type cases; ...        (The Lancet)   \n",
       "2    BTK inhibitor class has reported DILI; monitor...               (PMC)   \n",
       "3    MS program experienced serious liver injury ca...      (Alyftrek HCP)   \n",
       "4    Trials reported liver enzyme elevations (class...              (Gene)   \n",
       "..                                                 ...                 ...   \n",
       "352                                                NaN                 NaN   \n",
       "353                                                NaN                 NaN   \n",
       "354                                                NaN                 NaN   \n",
       "355                                                NaN                 NaN   \n",
       "356                                                NaN                 NaN   \n",
       "\n",
       "                                   perplexity__Details  \\\n",
       "0                                                  NaN   \n",
       "1    FDA imposed partial clinical hold after liver ...   \n",
       "2    Partial clinical hold in December 2022 due to ...   \n",
       "3    Partial Phase III hold following reversible DI...   \n",
       "4    Hepatic transaminase grade ≥2 elevations more ...   \n",
       "..                                                 ...   \n",
       "352                                                NaN   \n",
       "353                                                NaN   \n",
       "354                                                NaN   \n",
       "355                                                NaN   \n",
       "356                                                NaN   \n",
       "\n",
       "                                        pubchem_smiles  \\\n",
       "0    CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4...   \n",
       "1    C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)O...   \n",
       "2    C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C...   \n",
       "3    C=CC(=O)N1CCC[C@H](C1)N2C3=C(C(=NC=C3)N)N(C2=O...   \n",
       "4    C[C@H]1CN(CCN1C2=CN=C(C=C2)NC3=CC(=CN(C3=O)C)C...   \n",
       "..                                                 ...   \n",
       "352  CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC   \n",
       "353  CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C...   \n",
       "354  C=CC(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=C...   \n",
       "355  C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C...   \n",
       "356  CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\\C(=O)N[C@H]2...   \n",
       "\n",
       "    dili_case_check Reasoning [Reasoning for the match decision]  \\\n",
       "0                                                  NaN             \n",
       "1                                                  NaN             \n",
       "2                                                  NaN             \n",
       "3                                                  NaN             \n",
       "4                                                  NaN             \n",
       "..                                                 ...             \n",
       "352  Multiple authoritative sources, including Live...             \n",
       "353  Anidulafungin has documented reports/signals o...             \n",
       "354  Multiple sources, including LiverTox and case ...             \n",
       "355  Pazufloxacin is listed in the FDA Drug-Induced...             \n",
       "356  Cefiderocol has reported transient aminotransf...             \n",
       "\n",
       "    dili_case_check Citations [Source citations for this match]  \\\n",
       "0                                                  NaN            \n",
       "1                                                  NaN            \n",
       "2                                                  NaN            \n",
       "3                                                  NaN            \n",
       "4                                                  NaN            \n",
       "..                                                 ...            \n",
       "352  https://pubchem.ncbi.nlm.nih.gov/compound/Perg...            \n",
       "353  https://www.sciencedirect.com/topics/biochemis...            \n",
       "354  https://journals.lww.com/ajg/fulltext/2017/100...            \n",
       "355  https://pmc.ncbi.nlm.nih.gov/articles/PMC61815...            \n",
       "356                                                NaN            \n",
       "\n",
       "                                      URL [Entity URL]  \\\n",
       "0                                                  NaN   \n",
       "1                                                  NaN   \n",
       "2                                                  NaN   \n",
       "3                                                  NaN   \n",
       "4                                                  NaN   \n",
       "..                                                 ...   \n",
       "352                   ncbi.nlm.nih.gov/books/NBK548593   \n",
       "353  frontiersin.org/journals/pharmacology/articles...   \n",
       "354                   ncbi.nlm.nih.gov/books/NBK548449   \n",
       "355  fda.gov/science-research/liver-toxicity-knowle...   \n",
       "356                   ncbi.nlm.nih.gov/books/NBK547862   \n",
       "\n",
       "                                                        \\\n",
       "0                                                  NaN   \n",
       "1                                                  NaN   \n",
       "2                                                  NaN   \n",
       "3                                                  NaN   \n",
       "4                                                  NaN   \n",
       "..                                                 ...   \n",
       "352  https://www.ncbi.nlm.nih.gov/books/NBK548593/,...   \n",
       "353  https://www.ncbi.nlm.nih.gov/books/NBK548299/,...   \n",
       "354  https://onlinelibrary.wiley.com/doi/full/10.10...   \n",
       "355                                                NaN   \n",
       "356                                                NaN   \n",
       "\n",
       "                                                smiles  \n",
       "0    CC[C@H]1[C@@H](O)[C@@H]2[C@H](CC[C@]3(C)[C@@H]...  \n",
       "1    C=CC(=O)N1CCC(CN=c2[nH]cnc(N)c2-c2ccc(Oc3ccccc...  \n",
       "2    C=CC(=O)N1CCC(c2ccc(C(N)=O)c(-c3ccc(Oc4ccccc4)...  \n",
       "3    C=CC(=O)N1CCC[C@@H](n2c(=O)n(-c3ccc(Oc4ccccc4)...  \n",
       "4    C[C@H]1CN(C2COC2)CCN1c1ccc(=Nc2cc(-c3ccnc(N4CC...  \n",
       "..                                                 ...  \n",
       "352  CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@...  \n",
       "353  CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)NC4C[C@@H](O)[C...  \n",
       "354  C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)...  \n",
       "355  C[C@H]1COc2c(C3(N)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23  \n",
       "356  CC(C)(ON=C(C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]...  \n",
       "\n",
       "[357 rows x 18 columns]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = df[~df[\"DILI_labels\"].isna() & ~df[\"standardized_smiles\"].isna()].rename(columns={\"Name\": \"compound_name\", \"DILI_labels\": \"is_dili\", \"standardized_smiles\": \"smiles\"})\n",
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "a499ff64",
   "metadata": {},
   "outputs": [],
   "source": [
    "df[[\"compound_name\", \"is_dili\", \"smiles\"]].to_csv(\"recent_dili.csv\", index=False)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "chemeleon-dev",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
